Biotech Values

[ghmm]

BMY / NKTR:

I heard the call it was (surprisingly) quite brief. They gave out some data on the ongoing MAD study and I think that is why the stock is down. I thought it especially unusual that they would not have slides or PR the data I'd have to go back and listen more closely to get what they did reveal. There were no RECIST responses thus far but I believe 9 (of 16?) continue on treatment. I believe they have enrolled 23 thus far. The safety seems to be a non-issue thus far with I believe one or two (grade 3) SAE's that were transient (responded to fluids) and I believe 1 discontinuation (injection site reaction but they said person also had same to an MAB).

On the BMS deal they have 2 year right of first negotiation. Then afterwards they have 10 days to match any offer. More info is in the 8-k on that.

Sorry all this is rough I didn't take notes.